



ADULT MEDICATION GUIDELINE

Hyoscine Butylbromide

Scope (Staff):	All WNHS Staff
Scope (Area):	Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

Quick Links

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and Breastfeeding](#)

Restrictions

[Formulary: Unrestricted](#)

Medication Class

Anticholinergic. Smooth muscle relaxant; reduces GI motility and spasm.

Presentation

Tablet: 10mg

Ampoule: 20mg/mL

Storage

Tablet: Store at room temperature, below 25°C.

Ampoule: Store at room temperature, below 25°C. Protect from light.

Dose

Gastrointestinal spasm:

Oral:

10-20mg 3 to 4 times a day.

IM/IV Injection:

20-40mg up to every 30 minutes. Maximum 100mg daily.

Gastrointestinal Symptoms in Palliative Care

Refer to: Clinical Practice Guideline: [Palliative Care](#)

Respiratory Tract secretions at end of life

Refer to: [Therapeutic Guidelines](#) Last days of life: respiratory tract secretions

Administration

Refer to the [Australian Injectable Drugs Handbook](#)

Monitoring

Parenteral administration: Blood pressure, heart rate (can cause tachycardia, hypotension). Use with caution in patients with cardiac conditions. Some patients may experience blurred vision.

Pregnancy

1st Trimester: Considered safe to use.

2nd Trimester: Considered safe to use.

3rd Trimester: Considered safe to use.

Breastfeeding

Considered safe to use.

Related Policies, Procedures & Guidelines

WNHS Clinical Practice Guidelines:

[Palliative Care](#)

WNHS Pharmaceutical and Medicines Management Guidelines:

[Medication Administration](#)

[Prescribing Procedure](#)

References

Australian Medicines Handbook. Hyoscine butylbromide. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2023 [cited 2023 May 23]. Available from: <https://amhonline.amh.net.au/>

Society of Hospital Pharmacists of Australia. Hyoscine butylbromide. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2023 [cited 2023 May 23]. Available from: <http://aidh.hcn.com.au>

The Royal Women's Hospital. Hyoscine butylbromide. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2022 [cited 2023 May 23]. Available from: <https://thewomenspbmq.org.au/>

Therapeutic Guidelines. Pain: Management in Palliative Care. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2020 [cited 2023 May 23]. Available from: <https://tgidcdp.tg.org.au>

Therapeutic Guidelines. Terminal care: Last days of life: respiratory tract secretions. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2020 [cited 2023 Jun 09]. Available from <https://tgidcdp.tg.org.au>

MIMS Australia. Buscopan. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2021 [cited 2023 May 23]. Available from: <https://www.mimsonline.com.au>

Keywords	hyoscine, hyoscine butylbromide, Buscopan, palliative care, anti-spasmodic, anticholinergic, GI spasm, smooth muscle relaxant, respiratory tract secretions				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	5.0 Updated references and links; inclusion of Respiratory Tract secretions at end-of-life link.				
Date First Issued:	07/2015	Last Reviewed:	24/05/2023	Review Date:	24/05/2026
Endorsed by:	Medicines and Therapeutics Committee			Date:	01/08/2023
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2023

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.